Venture Capital for Swiss Proteomics Leader: Biognosys Raises CHF2.7m in Series A Financing
Biognosys, a Swiss ETH spin-off and pioneer in proteomics, has attracted venture capital from experienced...
Biognosys Collaborates with M2 to Develop Commercial MRM Software
Setting up scheduled multiplexed MRM experiments and processing MRM signals is a challenge in proteomics research. Biognosys’ proprietary software mQuest / mProphet, the RT-Kit and MRMbase assays resolve these issues (Reiter L, Rinner O et al. Nature Methods 2011, 8(5):430-435). Until now the company has utilised the software component for internal use only. The increased number of requests from industrial customers and the company’s aim for wide-spread MRM proteomics adoption led to a decision to develop a commercial MRM software product. Biognosys is glad to secure support from M2/Co-Services, a cutting-edge IT technology provider, for the software design and implementation.
For more information please contact Biognosys.
More About This Company
Biognosys Invited to Present its iRT Concept for Mass Spectrometry Specialists
On 29 September Biognosys is invited to present its iRT concept at the 'Mass Spectrometry...
Biognosys to Participate in the Tenth Annual World Congress of the Human Proteome Organisation in Geneva
Biognosys, a leading provider of targeted proteomics solutions, is attending the HUPO Tenth Annual World...